Supernus jumps 18.75% premarket on strong sales and Indivior merger announcement

INDV Indivior Pharmaceuticals Inc

$35.90 -0.25%

View chart & analysis →

SUPN +0.16% PFE +0.33% TSEM +3.54% CAT +1.80% ANET +4.09% 1 more

1. 1Supernus (SUPN) climbs 18.75% premarket after Q2 revenue beats estimates and announces all-stock merger of equals with Indivior (INDV)
2. 2Revenue of $219.10M exceeds consensus of $205.63M; full-year revenue guidance raised to $860M–$890M
3. 3Per-share loss of $1.01 reflects $54.9M non-cash impairment charge on APOKYN intangible assets; aims to launch diversified biopharmaceutical company focused on central nervous system disorder treatments

Source InvestorsHub +5 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →